Trial Profile

A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Sep 2017 Results assessing safety and efficacy of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma, were published in the Annals of Oncology.
17 Aug 2016 According to a Cerulean Pharma media release, the full data set from the trial are expected to be submitted for presentation at an upcoming medical conference.
17 Aug 2016 Results published in Cerulean Pharma Inc media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com